Promising combo for inflammatory breast cancer stalls after single patient

NCT ID NCT05198843

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)—in people with a rare, aggressive form of breast cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. However, the study was stopped early after only one person enrolled, so we have no useful information about whether the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)
What this could lead to
If it had worked, this combination might have pointed toward a new treatment option for a very aggressive breast cancer.
What could go wrong
The trial was terminated after enrolling only 1 person, so no meaningful conclusions can be drawn. It is too early to know if this combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.